Robot-Assisted Gastric ESD Is Feasible and Safe-Endoscopy Feb.26

Introduction

Endoscopic submucosal dissection (ESD) is the preferred curative treatment for early gastric cancer, but it remains technically demanding, largely because of poor traction and limited visualization during submucosal dissection. Multiple traction techniques have been proposed, yet most are either unstable, operator-dependent, or interrupt workflow.

Robotic assistance—particularly flexible traction robots—has shown promise in animal models by providing stable, adjustable, and continuous traction. Until now, however, clinical data in humans were lacking.

This pilot randomized trial represents the first real-world clinical evaluation of a traction robot–assisted ESD system for early gastric cancer.

Problem statement

The main challenges in gastric ESD are:

• maintaining optimal traction throughout dissection,
• avoiding muscularis propria injury,
• and reducing technical difficulty without compromising oncologic outcomes.

Whether robotic traction can improve safety or procedure efficiency in actual patients—beyond experimental models—has been unknown.

What the study did:

• Prospective, single-blind, randomized pilot trial
• Patients with high-grade intraepithelial neoplasia or intramucosal gastric cancer
• Randomized to:
• Robot-assisted ESD (flexible single-arm traction robot), or
• Conventional ESD
• Performed in a tertiary referral center by experienced endoscopists

Primary focus: procedure feasibility and safety, with procedure time as the main endpoint.

Key findings clinicians should remember

1. Robot-assisted gastric ESD is feasible and safe

All procedures were completed successfully, with no perforations in either group. This is the most important first signal for any new ESD technology.

2. Oncologic outcomes were equivalent

• En bloc resection and R0 resection rates were similar between robotic and conventional ESD.

👉 This confirms that robotic assistance does not compromise curative intent.

3. Fewer muscular injuries with robotic traction

Robot-assisted ESD significantly reduced muscularis propria injuries, suggesting:

• better traction control,
• more stable dissection planes,
• and potentially lower risk of delayed complications.

4. No clear reduction in overall procedure time—yet

Overall procedure time was not significantly shorter with robotic assistance.

However, a learning-curve signal was evident: in later cases, robot-assisted ESD times trended shorter than conventional ESD.

👉 This suggests the true efficiency benefit may emerge after familiarization, not in early pilot experience.

Clinical interpretation

This study should be viewed as a proof-of-concept, not a practice-changing trial.

Key messages for endoscopists:

• Robotic traction works in real patients.
• It appears to improve safety margins by reducing muscular injury.
• It does not slow down ESD once operators gain experience.
• Oncologic quality is preserved.

The absence of clear time savings is expected in a pilot randomized trial and should not be overinterpreted.

Bottom-line takeaway

Traction robot–assisted gastric ESD is clinically feasible, safe, and oncologically sound, with early signals of improved procedural safety. Larger trials are now needed to determine whether robotic traction can meaningfully reduce complications, shorten learning curves, or expand access to high-quality ESD.

One-line GastroAGI takeaway

Robotic traction can safely assist gastric ESD and may reduce muscular injury without compromising resection quality.